Find a Research Study

Renal Disease Research Institute (RDRI) is a research entity affiliated with Dallas Nephrology Associates. For 50 years years, Dallas Nephrology Associates has been caring for patients with kidney disease, hypertension, transplants and complicated electrolyte disorders. The Research Institute allows us to conduct clinical trials that will improve our future ability to treat kidney disease and give our patients the opportunity to receive cutting-edge therapy.  At RDRI, there is significant ethical oversight of this entity through RDRI’s Board of Managers and Scientific Review Committee.

Choosing to participate in a study is an important personal decision. Are you interested in participating in a study?  Talk with your doctor and family members or friends about deciding to join a study.

  • Treatment for Patients with Fabry Disease
  • Patients with hyperkalemia and metabolic acidosis associated with CKD
  • Treatment of CMV infection in Kidney Transplant Recipients
  • Patients with Anemia Associated with Chronic Kidney Disease
  • Autosomal dominant polycystic kidney disease
  • Immunoglobulin A (IgA) nephropathy
  • Patients with High blood Pressure & IgA
  • Chronic active antibody-mediated rejection in kidney transplant recipients
  • Patients with CKD at risk of rapid progression
  • Treatment of BK Viremia in Kidney Transplant Recipients
  • Patients with Enteric Hyperoxaluria

Updated 6/3/21:

Protocol Name: A Phase 2, Open-Label, Basket Study of Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study)

Indication: Proteinuric Glomerular Disease – IgAN, FSGS, Alport Syndrome, Diabetic Kidney disease

Primary Investigator: Dr. Akinwande Akinfolarin

Location: Landry office – 411 N. Washington Ave Suite 7000, Dallas, TX 75246

 

Protocol Name: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study)

Indication: Patients with IgA Nephropathy at Risk of Progressive loss of renal function

Primary Investigator: Dr. Akinwande Akinfolarin

Location: Landry office – 411 N. Washington Ave Suite 7000, Dallas, TX 75246

 

Protocol Name: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of NPC-21 for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection (LionHeart21)(New)

Primary Investigator: Dr. Arthi Rajagopal

Indication: Treatment of CMV infection in Kidney Transplant Recipients

Location: Corporate office -1420 VICEROY DRIVE DALLAS, TX 75235

 

Protocol Name: A Double-blind Randomized Placebo-controlled Parallel Design Multicenter Phase IIIb Study of the Effect of Sodium Zirconium On Serum Potassium and Serum Bicarbonate in Patients with Hyperkalemia and Metabolic Acidosis Associated with Chronic Kidney Disease (NEUTRALIZE)(New)

Primary Investigator: Dr. Harold Szerlip

Indication: Patients with hyperkalemia and metabolic acidosis associated with CKD

Location: Landry Office – 411 N. WASHINGTON AVENUE SUITE 7000 DALLAS, TX 75246

 

Protocol Name:Expanded Access Treatment with Open-Label Pegunigalsidase Alfa for Fabry Patients (Fabry)(New)

Primary Investigator: Dr. Ankit Mehta

Indication: Treatment for Patients with Fabry Disease

Location: Corporate office -1420 VICEROY DRIVE DALLAS, TX 75235

 

Protocol Name:  A repeat dose, open label, two period, randomized, cross over study to compare the effect of daprodustat to recombinant, human erythropoietin on oral  iron absorption in adult participants with anemia associated with chronic kidney disease who are not on dialysis”

Indication: Patients with Anemia Associated with Chronic Kidney Disease

PI: Dr. Bernard Fischbach

Location: Fort Worth office -1250 Eighth Ave, Suite 135 Fort Worth, TX 76104

 

Protocol Name: A phase 3 trial of the efficacy and safety of bardoxolone methyl in patients with autosomal dominant polycystic kidney disease. (Falcon)

Indication: Autosomal dominant polycystic kidney disease – PKD

PI: Dr. Ankit Mehta

Location: Corporate office -1420 VICEROY DRIVE DALLAS, TX 75235

 

Protocol Name: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS-IGAN). (Omeros)

Indication: Immunoglobin nephropathy – IgA

PI: Dr. Harold Szerlip

Location: Landry Office – 411 N. WASHINGTON AVENUE SUITE 7000 DALLAS, TX 75246

 

Protocol Name: A Multi-Center Open-label Investigation to Assess the Safety and Efficacy of Multiple Doses of DM199 in Patients with Chronic Kidney Disease (Stage II or III)” (Diamedica)

Indication: Patients with High blood Pressure & IgA

PI: Dr. Venkata Yalamanchilli

Location: Charlton Office – 2651 BOLTON BOONE DR. DESOTO, TX 75115

 

Protocol Name: Clinical study protocol a pivotal phase 3 trial to evaluate the safety and efficacy of clazakizumab for the treatment of chronic active antibody-mediated rejection in kidney transplant recipients (Imagine)

Indication: Chronic active antibody-mediated rejection in kidney transplant recipients

PI: Dr. Bernard Fischbach

Location: Corporate office – 1420 VICEROY DRIVE DALLAS, TX 75235

 

Protocol Name: A phase 2 trial to evaluate safety, tolerability, and efficacy of bardoxolone methyl in patients with chronic kidney disease at risk of rapid progression (Merlin)

Indication: Patients with CKD at risk of rapid progression

PI: Dr. Tapan Patel

Location: Location: Corporate office -1420 VICEROY DRIVE DALLAS, TX 75235

 

Protocol Name: A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients (Amplyx)

PI: Dr. Bernard Fischbach

Indication: Treatment of BK Viremia in Kidney Transplant Recipients

Location: Corporate office – 1420 VICEROY DRIVE DALLAS, TX 75235

 

Protocol Name: Establishing the Safety and Efficacy of Reloxaliase in Patients with Enteric Hyperoxaluria: A Phase III Randomized, Double-blind, Placebo-Controlled Study. (Allena 302)

PI: Dr. Michael Wiederkher

Indication: Patients with Enteric Hyperoxaluria

Location: Location: Corporate office -1420 VICEROY DRIVE DALLAS, TX 75235